TY - JOUR
T1 - Advantages of the lipoprotein-associated phospholipase A2 activity assay
AU - Donato, Leslie J.
AU - Meeusen, Jeffrey W.
AU - Callanan, Heidi
AU - Saenger, Amy K.
AU - Jaffe, Allan S.
N1 - Publisher Copyright:
© 2015 The Canadian Society of Clinical Chemists.
PY - 2016/1/1
Y1 - 2016/1/1
N2 - Objectives: Lipoprotein-associated phospholipase A2 (Lp-PLA2) is increased in circulation in patients at higher risk of coronary heart disease (CHD) events and stroke. Therefore, measurement of Lp-PLA2 can be used as an adjunct to traditional cardiovascular risk factors for identifying individuals at higher risk of cardiovascular events. Recently, a reagent for measuring Lp-PLA2 activity (diaDexus, San Francisco, CA) received FDA approval. Here we evaluate the assay performance of the Lp-PLA2 activity assay.Methods: Lp-PLA2 activity assay reagent performance was evaluated on an open user-defined channel on a Cobas 6000/c501 (Roche Diagnostics, Indianapolis, IN) using a 5-point calibration curve (0-400nmol/min/mL). Analytical performance was established for the following parameters: precision, linearity, accuracy, analytical sensitivity, analytical specificity, reference interval, reagent lot-to-lot comparison, specimen type, on-board reagent stability, and sample stability.Results: Assay limit of detection was determined to be 7.8nmol/min/mL with an average %CV of 2.8%. Precision studies revealed a coefficient of variation ≤1.6% between 79 and 307 nmol/min/mL and accuracy was demonstrated between 4.8-368.7 nmol/min/mL. Comparable results were generated in paired SST serum and EDTA plasma. No age association was found with Lp-PLA2 activity at the 95th percentile however a gender association was identified resulting in gender-specific 95th percentile limits in a healthy reference population. No bias was found when comparing results from several different lots of assay reagent. Lp-PLA2 activity results are extremely stable in both serum and EDTA plasma under refrigerate and frozen storage conditions up to 31days.Conclusions: Lp-PLA2 activity assay displays accurate and precise performance characteristics on the Cobas c501 platform. The assay performance is significantly improved over the predecessor immunoassay allowing for adoption of Lp-PLA2 activity in clinical practice.
AB - Objectives: Lipoprotein-associated phospholipase A2 (Lp-PLA2) is increased in circulation in patients at higher risk of coronary heart disease (CHD) events and stroke. Therefore, measurement of Lp-PLA2 can be used as an adjunct to traditional cardiovascular risk factors for identifying individuals at higher risk of cardiovascular events. Recently, a reagent for measuring Lp-PLA2 activity (diaDexus, San Francisco, CA) received FDA approval. Here we evaluate the assay performance of the Lp-PLA2 activity assay.Methods: Lp-PLA2 activity assay reagent performance was evaluated on an open user-defined channel on a Cobas 6000/c501 (Roche Diagnostics, Indianapolis, IN) using a 5-point calibration curve (0-400nmol/min/mL). Analytical performance was established for the following parameters: precision, linearity, accuracy, analytical sensitivity, analytical specificity, reference interval, reagent lot-to-lot comparison, specimen type, on-board reagent stability, and sample stability.Results: Assay limit of detection was determined to be 7.8nmol/min/mL with an average %CV of 2.8%. Precision studies revealed a coefficient of variation ≤1.6% between 79 and 307 nmol/min/mL and accuracy was demonstrated between 4.8-368.7 nmol/min/mL. Comparable results were generated in paired SST serum and EDTA plasma. No age association was found with Lp-PLA2 activity at the 95th percentile however a gender association was identified resulting in gender-specific 95th percentile limits in a healthy reference population. No bias was found when comparing results from several different lots of assay reagent. Lp-PLA2 activity results are extremely stable in both serum and EDTA plasma under refrigerate and frozen storage conditions up to 31days.Conclusions: Lp-PLA2 activity assay displays accurate and precise performance characteristics on the Cobas c501 platform. The assay performance is significantly improved over the predecessor immunoassay allowing for adoption of Lp-PLA2 activity in clinical practice.
KW - Assay validation
KW - Biomarkers
KW - Lipoprotein-associated phospholipase A2
KW - Lp-PLA
KW - PLAC activity
KW - Platelet activating factor acetylhydrolase
UR - http://www.scopus.com/inward/record.url?scp=84953348321&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84953348321&partnerID=8YFLogxK
U2 - 10.1016/j.clinbiochem.2015.09.002
DO - 10.1016/j.clinbiochem.2015.09.002
M3 - Article
C2 - 26365697
AN - SCOPUS:84953348321
SN - 0009-9120
VL - 49
SP - 172
EP - 175
JO - Clinical Biochemistry
JF - Clinical Biochemistry
IS - 1
ER -